We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+0.36%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$782M
AUM Growth
+$134M
Cap. Flow
-$119M
Cap. Flow %
-15.2%
Top 10 Hldgs %
66.62%
Holding
166
New
28
Increased
41
Reduced
46
Closed
40

Top Buys

Rank Stock Value
1
ORMP icon
Oramed Pharmaceuticals
ORMP
+$4.16M
2
NKTR icon
Nektar Therapeutics
NKTR
+$3.04M
3
VKTX icon
Viking Therapeutics
VKTX
+$1.95M
4
FOLD
Amicus Therapeutics
FOLD
+$1.63M
5
GNPX icon
Genprex
GNPX
+$1.42M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$40.1M
2
NVO
Novo Nordisk
NVO
+$19.8M
3
SSKN
Strata Skin Sciences
SSKN
+$3.45M
4
INCY icon
Incyte
INCY
+$2.77M
5
AZN icon
AstraZeneca
AZN
+$2.59M

Sector Composition

Rank Sector Weight
1 Healthcare 15.01%
2 Consumer Staples 0.29%
3 Financials 0.12%
4 Technology 0.09%
5 Materials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
51
Dianthus Therapeutics
DNTH
$5.55B
$1.13M 0.14%
5,889
+1,151
+24% +$242K
XYLO
52
DELISTED
Xylo Technologies
XYLO
$1.01M 0.13%
+7,418
New +$1.03M
CATX icon
53
Perspective Therapeutics
CATX
$327M
$999K 0.13%
+192,549
New +$1.07M
NXTP
54
DELISTED
NextPlay Technologies, Inc. Common Stock
NXTP
$956K 0.12%
+22,229
New +$1.1M
VKTX icon
55
CALL
Viking Therapeutics
VKTX
$3.93B
$941K 0.12%
540
-554
-51% -$6.59K
MDGSW
56
DELISTED
Medigus Ltd. Series C Warrant
MDGSW
$926K 0.12%
+1,268,146
New +$754K
PAVMZ
57
DELISTED
PAVmed Inc. Series Z Warrant
PAVMZ
$915K 0.12%
1,946,838
-181,862
-9% -$90.3K
SGYPW
58
CALL
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$915K 0.12%
5,382
+128
+2% +$21.8K
INSM icon
59
PUT
Insmed
INSM
$22.6B
$833K 0.11%
412
-1,249
-75% -$28.2K
AMRN
60
PUT
Amarin Corp
AMRN
$293M
$828K 0.11%
25
-30
-55% -$2.27K
ATOS icon
61
Atossa Therapeutics
ATOS
$24.1M
$814K 0.1%
31,003
+8,286
+36% +$271K
RIBT
62
DELISTED
RiceBran Technologies
RIBT
$807K 0.1%
+28,106
New +$785K
OPNT
63
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$781K 0.1%
+43,736
New +$758K
EIDX
64
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$766K 0.1%
76,740
+26,907
+54% +$442K
KYNB
65
Kyntra Bio
KYNB
$28.2M
$730K 0.09%
481
+61
+15% +$93.9K
NOVN
66
DELISTED
Novan, Inc. Common Stock
NOVN
$700K 0.09%
25,096
-21,194
-46% -$587K
SNES icon
67
SenesTech
SNES
$7.11M
$675K 0.09%
+20
New +$1.03M
HYPD
68
Hyperion DeFi Inc
HYPD
$36.7M
$657K 0.08%
2,042
+365
+22% +$163K
GLMD icon
69
Galmed Pharmaceuticals
GLMD
$4.41M
$599K 0.08%
245
-1,045
-81% -$2.45M
ALDX icon
70
CALL
Aldeyra Therapeutics
ALDX
$95.3M
$589K 0.08%
+427
New +$3.46K
VIRX
71
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$556K 0.07%
7,948
-6,682
-46% -$507K
SCON
72
DELISTED
Superconductor Technologies Inc.
SCON
$533K 0.07%
28,795
+28,568
+12,585% +$1.15M
NUWE icon
73
Nuwellis
NUWE
$178K
– –
0
– –
NURO
74
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$496K 0.06%
4,661
+362
+8% +$36.7K
KA
75
DELISTED
Kineta, Inc. Common Stock
KA
$482K 0.06%
+1,428
New +$509K
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2018 Portfolio in Review

As of Q3 2018, Sabby Management held 166 positions worth $782M, up 21% from $647M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Sabby Management withdrew a net $119M in Q3 2018, closing 40 positions and reducing 46 holdings. Its most notable exit was Novo Nordisk, an estimated $19.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 26% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Sabby Management opened a new position in Oramed Pharmaceuticals worth $3.88M.

  • Sabby Management's largest Q3 2018 buy was Oramed Pharmaceuticals: 801,242 shares worth $3.88M.
  • Sabby Management added most to Nektar Therapeutics in Q3 2018, an estimated $3.04M increase.
  • Sabby Management's biggest Q3 2018 reduction was Biogen, cutting an estimated $40.1M.
  • Sabby Management fully exited Novo Nordisk in Q3 2018, selling an estimated $19.8M.
  • Sabby Management's ten largest holdings make up 67% of its $782M portfolio in Q3 2018.
  • Sabby Management opened 28 new positions and closed 40 in Q3 2018.
  • Sabby Management's portfolio value rose 21% quarter-over-quarter to $782M.

Based on Sabby Management's 13F filing for Q3 2018, filed 14 Nov 2018.